Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
- Conditions
- Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
- Registration Number
- NCT04247906
- Lead Sponsor
- Omeros Corporation
- Brief Summary
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Narsoplimab MASP-2 inhibition mechanism lectin pathway complement HSCT-TMA pathophysiology endothelial injury
Comparative effectiveness Narsoplimab versus eculizumab supportive care HSCT-TMA treatment outcomes survival
Biomarkers predicting HSCT-TMA severity response Narsoplimab MASP-2 inhibition complement activation markers
Safety profile adverse events MASP-2 inhibitors Narsoplimab complement inhibition HSCT infection risk
MASP-2 inhibitors lectin pathway targeting drugs thrombotic microangiopathy clinical pipeline Omeros competitors